Evidence map›Paper›PMID 35940363›Full record

ArticleJournal of vascular and interventional radiology : JVIR2022

Evaluation of an Integrated Spectroscopy and Classification Platform for Point-of-Care Core Needle Biopsy Assessment: Performance Characteristics from Ex Vivo Renal Mass Biopsies.

Krishna Nand Keshavamurthy, Dmitry V Dylov, Siavash Yazdanfar, Dharam Patel, Tarik Silk, Mikhail Silk, Frederick Jacques, Elena N Petre, Mithat Gonen, Natasha Rekhtman and 4 more

Open access · greenAbstract read
In one paragraph

Article in Journal of vascular and interventional radiology : JVIR, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.3field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 1 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 7 institutions in 2 countries.

Krishna Nand KeshavamurthyDepartment of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York.
Dmitry V DylovSkolkovo Institute of Science and Technology, Moscow, Russia.
Siavash YazdanfarCorning Incorporated, Corning, New York.
Dharam PatelNovartis Pharmaceutical Corporation, East Hanover, New Jersey.
Tarik SilkNew York University Langone Medical Center, New York, New York.
Mikhail SilkDepartment of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York.
Frederick JacquesMontefiore Medical Center, New York, New York.
Elena N PetreDepartment of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York.
Mithat GonenDepartment of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York.
Natasha RekhtmanDepartment of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York.
Victor OstroverkhovGE Global Research, Niskayuna, New York.
Howard I ScherDepartment of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.
Stephen B SolomonDepartment of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York.
Jeremy C DurackDepartment of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York. Electronic address: jcdurack@gmail.com.
Memorial Sloan Kettering Cancer Center · USCorning (United States) · USGE Global Research (United States) · USMontefiore Medical Center · USNovartis (United States) · USNYU Langone Health · USSkolkovo Institute of Science and Technology · RU

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Hongbiao Carl Lekaye · 1985 to 2026
$347.4M
NCI NIH HHS P30 CA008748
6 · The paper itself

Abstract

purposeTo evaluate a transmission optical spectroscopy instrument for rapid ex vivo assessment of core needle cancer biopsies (CNBs) at the point of care. MATERIALS AND

methodsCNBs from surgically resected renal tumors and nontumor regions were scanned on their sampling trays with a custom spectroscopy instrument. After extracting principal spectral components, machine learning was used to train logistic regression, support vector machines, and random decision forest (RF) classifiers on 80% of randomized and stratified data. The algorithms were evaluated on the remaining 20% of the data set held out during training. Binary classification (tumor/nontumor) was performed based on a decision threshold. Multinomial classification was also performed to differentiate between the subtypes of renal cell carcinoma (RCC) and account for potential confounding effects from fat, blood, and necrotic tissue. Classifiers were compared based on sensitivity, specificity, and positive predictive value (PPV) relative to a histopathologic standard.

resultsA total of 545 CNBs from 102 patients were analyzed, yielding 5,583 spectra after outlier exclusion. At the individual spectra level, the best performing algorithm was RF with sensitivities of 96% and 92% and specificities of 90% and 89%, for the binary and multiclass analyses, respectively. At the full CNB level, RF algorithm also showed the highest sensitivity and specificity (93% and 91%, respectively). For RCC subtypes, the highest sensitivity and PPV were attained for clear cell (93.5%) and chromophobe (98.2%) subtypes, respectively.

conclusionsEx vivo spectroscopy imaging paired with machine learning can accurately characterize renal mass CNB at the time of tissue acquisition.

Indexed as

Carcinoma, Renal CellKidney NeoplasmsBiopsy, Large-Core NeedleHumansPoint-of-Care SystemsSpectrum Analysis

Identifiers

PMID35940363
PMCPMC10204606
OpenAlexW4292542410

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.